Clinical Trial Update: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL [Phase 3]

View source ↗

Summary

Phase 3 trial update on acalabrutinib with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Chlorambucil (chlorambucil)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-01-10